Recombinetics and Children’s Minnesota Collaborate to Develop Customized Swine Medical Model of Phenylketonuria
Recombinetics today announced a multi-year, exclusive collaborative research and development agreement with Children’s Minnesota, the seventh largest pediatric healthcare system in the country, to produce the first-ever large animal model of Phenylketonuria (PKU). PKU is one of the most common inborn errors of metabolism with a cumulative incidence of approximately [...]
RCI Names Dr. Mitchell Abrahamsen as EVP & CCO
Recombinetics (RCI) announced that Dr. Mitchell Abrahamsen has joined RCI as Executive Vice President and Chief Commercial Officer. Dr. Abrahamsen will lead product and business development efforts for RCI and its subsidiaries that are commercializing gene-edited animal models for biomedical and agricultural use, Acceligen and Surrogen. Abrahamsen will also continue to [...]
Recombinetics Announces Major Advancements in the Development of a Novel Swine Model of Neurofibromatosis Type 1
Recombinetics announced the development of the first-of-their-kind gene-edited swine models for Neurofibromatosis Type 1 (NF1). Partially funded by the Children’s Tumor Foundation, and in collaboration with the University of Minnesota, these models are for use in preclinical safety and efficacy testing of therapeutics for this debilitating genetic disease affecting 1 [...]